Clinical Trial Update: Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC [Phase 2]

View source ↗

Summary

A Phase II trial evaluating pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University College, London | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING